Deferasirox BID (Twice a Day) in Transfusion Dependent Thalassemia Patients With Inadequate Response to High Doses

Clinical trial NCT01948817 · WITHDRAWN

Trial details

NCT number: NCT01948817
Sponsor: Novartis Pharmaceuticals
Status: WITHDRAWN
Phase: Phase 2
Study type: INTERVENTIONAL

Focus on Transfusion Dependent Thalassemia Patients Who Are Inadequate Responders to Deferasirox > 35mg/kgQD

Start date: 2014-02-01
Primary completion: 2016-02-01
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.